相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb et al.
EUROPEAN UROLOGY (2021)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive for Prostate Cancer
Konrad H. Stopsack et al.
CLINICAL CANCER RESEARCH (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
DNA Repair and Prostate Cancer: A Field Ripe for Harvest
Alan H. Bryce et al.
EUROPEAN UROLOGY (2020)
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Stephen J. Pettitt et al.
CANCER DISCOVERY (2020)
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
Mark C. Markowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy
Yanke Chen et al.
NATURE CELL BIOLOGY (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
Catherine H. Marshall et al.
EUROPEAN UROLOGY (2019)
Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets
Samuele Lodovichi et al.
Oncotarget (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (vol 174, pg 758, 2018)
David A. Quigley et al.
CELL (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The E3 Ubiquitin Ligase ARIH1 Protects against Genotoxic Stress by Initiating a 4EHP-Mediated mRNA Translation Arrest
Louise von Stechow et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Budding Yeast ATM/ATR Control Meiotic Double-Strand Break (DSB) Levels by Down-Regulating Rec114, an Essential Component of the DSB-machinery
Jesus A. Carballo et al.
PLOS GENETICS (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
分享论文
